A5050141381- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- Cancer Genomics and Diagnostics
- Health Systems, Economic Evaluations, Quality of Life
- Pituitary Gland Disorders and Treatments
- Lung Cancer Research Studies
- Gastric Cancer Management and Outcomes
- BRCA gene mutations in cancer
- Colorectal Cancer Treatments and Studies
- Global Cancer Incidence and Screening
- Radiomics and Machine Learning in Medical Imaging
- Multiple and Secondary Primary Cancers
- Chronic Lymphocytic Leukemia Research
- Ovarian cancer diagnosis and treatment
- Advanced Breast Cancer Therapies
- Pancreatic and Hepatic Oncology Research
- Pharmaceutical Economics and Policy
- Lymphoma Diagnosis and Treatment
- Cancer Diagnosis and Treatment
- Adrenal and Paraganglionic Tumors
- Innovation Policy and R&D
- Renal cell carcinoma treatment
- Cerebrospinal fluid and hydrocephalus
- Growth Hormone and Insulin-like Growth Factors
AstraZeneca (Canada)
2018-2021
New York University Press
2009-2020
Cambridge University Press
2009-2020
Royal Australasian College of Surgeons
2020
The University of Adelaide
2020
Agencia de Evaluación de Tecnologías Sanitarias
2020
AstraZeneca (United States)
2019
Novartis (Canada)
2012-2016
Office of Naval Research
2012
University of York
2009
Background: With recent advances in the treatment of non-small-cell lung cancer (NSCLC) and current fiscal constraints within publicly funded health care systems, understanding real-world economic effect management has become important. The objective present study was to determine costs resources used nsclc cohorts Ontario. Methods: Patients diagnosed between 1 April 2010 31 March 2015 were identified Ontario Cancer Registry linked provincial administrative databases, capturing such as...
Background Crizotinib was the first agent approved for treatment of anaplastic lymphoma kinase (ALK)– positive (+) non-small-cell lung cancer (NSCLC), followed by ceritinib. However, patients eventually progress or develop resistance to crizotinib. With limited real-world data available, objective present work evaluate patterns and survival after crizotinib in with locally advanced metastatic ALK+ NSCLC Canada. Methods In this retrospective study at 6 oncology centres across Canada, medical...
Methods: A retrospective cohort study considered patients 18 or more years of age diagnosed between January 2007 and May 2018 with unresectable stage iii non-small-cell lung cancer (nsclc) who received combined chemoradiation (crt). Survival was analyzed using the Kaplan–Meier method to determine median overall (os) progression-free survival (pfs) associated 95% confidence intervals (cis). Cox regression analysis performed identify factors prognostic for survival, including age, sex, smoking...
Background: To assess the cost-effectiveness of ceritinib vs alternatives in patients who discontinue treatment with crizotinib anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) from a Canadian public healthcare perspective.Methods: A partitioned survival model three health states (stable, progressive, and death) was developed. Comparators were chosen based on reported utilization retrospective chart study; comparators pemetrexed, best supportive care (BSC),...
Background: Most patients with stage III non–small cell lung cancer (NSCLC) develop metastases and succumb to their cancer. Approaches the treatment of disease can be highly variable. Understanding current patterns inform optimal integration emerging therapies. In this study, we describe contemporary outcomes for a population-based cohort NSCLC from large Canadian province. Methods: On basis provincial registry, all adult diagnosed April 1, 2010 March 31, 2015 were identified. Analyses these...
Background: Almost half of all patients with non-small-cell lung cancer (nsclc) present stage iv disease. The objective the study was to characterize treatment patterns and survival outcomes in advanced nsclc. Methods: We conducted a longitudinal population-level diagnosed nsclc Ontario between 1 April 2010 31 March 2015, follow-up 2017 for overall sequence. Patients were stratified as nonsquamous or squamous histology. A sub-analysis histology who received targeted therapies, on assumption...
As the treatment landscape in patients with non-small cell lung cancer (NSCLC) harboring mutations epidermal growth factor receptor (EGFRm) continues to evolve, real-world health utility scores (HUS) become increasingly important for economic analyses.In an observational cohort study, questionnaires were completed EGFRm NSCLC outpatients, include demographics, EQ-5D-based HUS and patient-reported toxicity symptoms. Clinical radiologic characteristics together outcomes extracted from chart...
Objectives To assess the cost effectiveness from a Canadian perspective of index patient germline BRCA testing and then, if positive, family members with subsequent risk-reducing surgery (RRS) in as yet unaffected mutation carriers compared no treatment cancer when it develops. Methods A level simulation was developed comparing outcomes between two groups using data. Group 1: developed. 2: cascade (index tested first-/second-degree relatives patient/first-degree relative is positive) RRS...
Background: The management of unresectable stage iii non-small-cell lung cancer (NSCLC) is complex and best determined through multidisciplinary consultation. A longitudinal, population-level study was carried out to describe the approach outcomes treatment in real-world setting Ontario. Methods: Individuals diagnosed with nsclc between 1 April 2010 31 March 2015 were identified Ontario Cancer Registry. Unresectable disease defined as no surgery reported within 3 months diagnosis. Initial...
ObjectivesTreatment of advanced NSCLC (aNSCLC) is rapidly evolving, as new targeted and immuno-oncology (I-O) treatments become available. The iTEN model was developed to predict the cost survival benefits changing aNSCLC treatment patterns from a Canadian healthcare system perspective. This report describes development validation.Materials & methodsA discrete event patient simulation developed. A modified Delphi process using clinical experts informed sequences that included commonly used,...
Information on the real-world experience of Canadians diagnosed with chronic lymphocytic leukemia (CLL) is limited. This study was conducted to report treatment patterns and outcomes CLL using Ontario administrative data. A retrospective cohort in patients between 1 January 2010 31 December 2017 identified Cancer Registry (OCR). Data were accessed Institute Clinical Evaluative Sciences (ICES), which collects various population-level health information. In Registry, 2887 receiving 2010-2017...
Background: In 2020, approximately 3100 Canadian women were diagnosed with ovarian cancer (OC), 1950 dying of this disease. Prognosis for OC remains poor, 70% to 75% cases at an advanced stage and overall 5-year survival 46%. Current standard care in Canada involves a combination cytoreductive surgery platinum-based chemotherapy. Objective: There are few studies reporting current costs. This study sought determine patient characteristics costs the health system Ontario, Canada. Methods:...
Objectives: There is considerable interest in the potential for harmonizing health technology assessments (HTA) across jurisdictions. This study aims to consider four HTAs of drug eluting stents determine degree which methods adopted, evidence considered, and resulting recommendations diverge. Methods: Four were selected inclusion evaluated using a framework developed systematically capture information on process considered each HTA. Results Conclusions: The findings suggest that, although...
The discovery of EGFR tyrosine kinase inhibitors (TKI) for the treatment mutant (EGFRm) metastatic NSCLC is regarded as a landmark in lung cancer. EGFR-TKIs have now become standard first-line EGFRm NSCLC. aim this retrospective cohort study to describe real-world patterns and outcomes patients with who received EGFR-TKI therapy outside clinical trials. One hundred seventy were diagnosed initiated on TKI between 2004 2018 at Peter Brojde Lung Cancer Centre Montreal. Following progression...
To assess the cost-effectiveness of ceritinib versus alternatives in patients who discontinue treatment with crizotinib anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) from a Canadian healthcare perspective. A partitioned survival model three health states (progression-free, progressive, and death) was developed to compare other ALK+ NSCLC were previously treated an ALK inhibitor. Comparators chosen based on reported utilization retrospective chart study;...
Everolimus and axitinib are approved to treat patients with metastatic renal cell carcinoma (mRCC) following failure on various first-line therapies. This analysis assessed the cost of care everolimus versus for second-line mRCC from a Canadian payer perspective. Costs considered in this included those related drug acquisition adverse events (AEs). Drug costs were based Ontario wholesaler price. Adverse event Case Costing Initiative literature. costs, adjusted dose intensity, AE daily...
Background: Treatment strategies for metastatic non–small cell lung cancer (NSCLC) are evolving rapidly and can be highly variable. Real-world evidence of treatment patterns outcomes provide an understanding our current practice offer insights on ways to incorporate emerging therapies into paradigm. In this population-based study, we investigated treatments stage IV NSCLC patients from a large Canadian province. Methods: Patients diagnosed with de novo April 1, 2010 March 31, 2015 were...
An abstract is not available for this content so a preview has been provided. As you have access to content, full PDF via the ‘Save PDF’ action button.